Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Richard A. Morgan(National Institutes of Health), James C. Yang(National Institutes of Health), Mio Kitano(National Institutes of Health), Mark E. Dudley(National Institutes of Health), Carolyn M. Laurençot(National Institutes of Health), Steven A. Rosenberg(National Institutes of Health)
Molecular Therapy
February 23, 2010
10.1038/mt.2010.24
Cited by 2,523Open Access
Full Text

Abstract

Related Papers

Untangling the ErbB signalling network
Yosef Yarden, Mark X. Sliwkowski|Nature Reviews Molecular Cell Biology|2001|6.9k
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Paul Carter, Leonard G. Presta, C Gorman et al.|Proceedings of the National Academy of Sciences|1992|1.9k
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Zelig Eshhar, Tova Waks, G. Gross et al.|Proceedings of the National Academy of Sciences|1993|1.6k
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito et al.|Molecular Therapy|2009|1.2k
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Michael F. Press, Carlos Cordon‐Cardo, Dennis J. Slamon|PubMed|1990|648